Yla-Herttuala S - Search Results

1

Experimental hyperlipidaemia does not prevent preconditioning and it reduces ischemia-induced apoptosis.

Dworakowski R, Dworakowska D, Kocic I, Wirth T, Gruchała M, Kamiński M, Ray R, Petrusewicz J, Yla-Herttuala S, Rynkiewicz A. Dworakowski R, et al. Int J Cardiol. 2008 May 7;126(1):62-7. doi: 10.1016/j.ijcard.2007.03.117. Epub 2007 May 4. Int J Cardiol. 2008. PMID: 17482295

2

Clinical significance of apoptotic index in non-small cell lung cancer: correlation with p53, mdm2, pRb and p21WAF1/CIP1 protein expression.

Dworakowska D, Jassem E, Jassem J, Karmoliński A, Dworakowski R, Wirth T, Gruchała M, Rynkiewicz A, Skokowski J, Yla-Herttuala S, Jaśkiewicz K, Czestochowska E. Dworakowska D, et al. J Cancer Res Clin Oncol. 2005 Sep;131(9):617-23. doi: 10.1007/s00432-005-0010-7. Epub 2005 Oct 20. J Cancer Res Clin Oncol. 2005. PMID: 16028106

3

Gene technology based therapies in the brain.

Wirth T, Ylä-Herttuala S. Wirth T, et al. Adv Tech Stand Neurosurg. 2006;31:3-32. doi: 10.1007/3-211-32234-5_1. Adv Tech Stand Neurosurg. 2006. PMID: 16768302 Review.

4

Cerivastatin and hypercholesterolemia reduce apoptosis of cardiomyocytes in guinea pig papillary muscle subjected to hypoxia/reoxygenation.

Dworakowski R, Dworakowska D, Kocic I, Wirth T, Gruchała M, Kamiński M, Petrusewicz J, Yla-Herttuala S, Rynkiewicz A. Dworakowski R, et al. Pharmacol Rep. 2006 May-Jun;58(3):420-6. Pharmacol Rep. 2006. PMID: 16845217 Free article.

5

Cell-type-specific characteristics modulate the transduction efficiency of adeno-associated virus type 2 and restrain infection of endothelial cells.

Pajusola K, Gruchala M, Joch H, Lüscher TF, Ylä-Herttuala S, Büeler H. Pajusola K, et al. J Virol. 2002 Nov;76(22):11530-40. doi: 10.1128/jvi.76.22.11530-11540.2002. J Virol. 2002. PMID: 12388714 Free PMC article.

6

Fibroblast growth factor 4 induces vascular permeability, angiogenesis and arteriogenesis in a rabbit hindlimb ischemia model.

Rissanen TT, Markkanen JE, Arve K, Rutanen J, Kettunen MI, Vajanto I, Jauhiainen S, Cashion L, Gruchala M, Närvänen O, Taipale P, Kauppinen RA, Rubanyi GM, Ylä-Herttuala S. Rissanen TT, et al. FASEB J. 2003 Jan;17(1):100-2. doi: 10.1096/fj.02-0377fje. Epub 2002 Nov 15. FASEB J. 2003. PMID: 12475908

7

Gene therapy for cardiovascular diseases.

Gruchala M, Roy H, Bhardwaj S, Ylä-Herttuala S. Gruchala M, et al. Curr Pharm Des. 2004;10(4):407-23. doi: 10.2174/1381612043453379. Curr Pharm Des. 2004. PMID: 14965202 Review.

8

Intravascular adenovirus-mediated lipoprotein-associated phospholipase A2 gene transfer reduces neointima formation in balloon-denuded rabbit aorta.

Turunen P, Puhakka H, Rutanen J, Hiltunen MO, Heikura T, Gruchala M, Ylä-Herttuala S. Turunen P, et al. Atherosclerosis. 2005 Mar;179(1):27-33. doi: 10.1016/j.atherosclerosis.2004.10.025. Epub 2004 Dec 13. Atherosclerosis. 2005. PMID: 15721006

9

Gene therapy: the first approved gene-based medicines, molecular mechanisms and clinical indications.

Räty JK, Pikkarainen JT, Wirth T, Ylä-Herttuala S. Räty JK, et al. Curr Mol Pharmacol. 2008 Jan;1(1):13-23. doi: 10.2174/1874467210801010013. Curr Mol Pharmacol. 2008. PMID: 20021420 Review.

10

VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses.

Rissanen TT, Markkanen JE, Gruchala M, Heikura T, Puranen A, Kettunen MI, Kholová I, Kauppinen RA, Achen MG, Stacker SA, Alitalo K, Ylä-Herttuala S. Rissanen TT, et al. Circ Res. 2003 May 30;92(10):1098-106. doi: 10.1161/01.RES.0000073584.46059.E3. Epub 2003 Apr 24. Circ Res. 2003. PMID: 12714562

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

755 results

Search Page